Altimmune Stock Sinks After Mid-Stage Data From Fatty Liver Candidate

benzinga.com/news/health-care/25/06/46116103/altimmune-stock-sinks-after-mid-stage-data-from-fatty-liver-candidate

On Thursday, Altimmune, Inc. (NASDAQ:ALT) released topline results from the IMPACT Phase 2b trial of pemvidutide in metabolic dysfunction-associated steatohepatitis (MASH).
Treatment discontinuation rates were low, with 9% of participants prematurely discontinuing treatment.
In an…

This story appeared on benzinga.com, 2025-06-26 13:56:25.
The Entire Business World on a Single Page. Free to Use →